Drug Profile
DVC LVS
Latest Information Update: 21 Dec 2015
Price :
$50
*
At a glance
- Originator DynPort Vaccine Company LLC
- Developer DynPort Vaccine Company; National Institute of Allergy and Infectious Diseases
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Tularaemia
Most Recent Events
- 21 Dec 2015 No recent reports on development identified - Phase-II for Tularaemia (Prevention, In volunteers) in USA (Intradermal)
- 03 Apr 2008 Tularaemia vaccine is still in clinical development
- 28 Feb 2007 Phase-I clinical trials in Tularaemia in USA (Intradermal)